Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /dom76025/wp-includes/functions.php on line 6121
FDA Accepts sBLA for Priority Review of Dupilumab for CRSwNP in Adolescents - The Dermatology Digest
Search

FDA Accepts sBLA for Priority Review of Dupilumab for CRSwNP in Adolescents

The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for dupilumab (Dupixent, Regeneron Pharmaceuticals & Sanofi) for Priority Review as an add-on maintenance treatment for adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

The target action date for the FDA decision is September 15, 2024. Dupilumab is currently approved as an add-on maintenance treatment for adults with CRSwNP whose disease is not adequately controlled.

The sBLA in adolescents is supported by an extrapolation of efficacy data from two positive pivotal trials (SINUS-24 and SINUS-52) in adults with CRSwNP. These trials demonstrated that Dupilumab significantly improved nasal congestion/obstruction severity, nasal polyp size and sense of smell, while also reducing the need for systemic corticosteroids or surgery, at 24 weeks compared to placebo. The sBLA was also supported by the safety data of Dupilumab in its currently approved indications for adolescents.

Safety results in both SINUS-24 and SINUS-52 were generally consistent with the known safety profile of Dupilumab in its approved indications. Adverse events more commonly observed with Dupilumab (≥3%) compared to placebo in SINUS-24 and SINUS-52 (24-week safety pool) were injection site reactions and arthralgia.